A Phase 3, Open-Label Single Arm Trial to Evaluate the Safety, Tolerability, and Immunogenicity of 3 Doses of 13-Valent Pneumococcal Conjugate Vaccine in Human Immunodeficiency Virus Subjects 18 Years of Age or Older

Grants and Contracts Details

StatusFinished
Effective start/end date1/20/10 → 12/31/14

Funding

  • Wyeth Pharmaceuticals Inc: $130,568.00